Despite the recorded reduction of epilepsy in high-income countries, the neurological condition persists as a severe disease affecting millions of people across the world. This non-communicable disease is also highly prevalent in children and is a leading cause of injury and deaths in the pediatric population. According to the Epilepsy Foundation, approximately 470,000 children in the U.S. are suffering from this disease. Seizures occurring in children are quite peculiar in nature and require an entirely different method of treatment. This has disrupted activity in the global anticonvulsants market where key players are striving to produce better results in children. As a consequence, R&D in the anticonvulsants market has a redirected focus on the production of newer age or second-generation antiepileptic drugs. These anti-seizure drugs are a step ahead of the antipsychotic first-generation medicines which often were reported to induce side effects in patients. Some of the second-generation antiepileptic drugs include valproic acid and gamma-aminobutyric acid, both of which are chemically derived anticonvulsants. This application segment of the anticonvulsants market will grow with a CAGR of 2.8% during the forecast period 2019-2025. Similarly, key market players are also delving into the field of natural anticonvulsants. Since chemically-derived antiepileptic drugs can have adverse side effects, studies on natural or organic ingredients as anticonvulsants are being carried out in major health institutions. For example, cilantro, an herb used for culinary purposes across the world, has been researched as one of the prime organic ingredients for reducing seizures. In a new study published in the FASEB Journal, scientists have explained how they have finally understood the reason behind cilantro acting as an organic anti-seizure drug. When consumed, cilantro activates channels of potassium present inside the brain, which helps in reducing seizures. These developments have helped the global anticonvulsants market in attaining noticeable growth. During the forecast period 2019-2025, the anticonvulsants market will grow with a CAGR of 3% and earned a revenue of $8.2 billion in 2018.
North America Leading the Global Anticonvulsants Market
According to IndustryARC’s research, North America has emerged as the regional leader of the anticonvulsants market with a share of 36% out of the total revenue earned by the market in 2018. Despite being a rare neurological disorder, epilepsy affects millions of patients every year. According to the Centers for Disease Control and Prevention, epilepsy impacts 1.2% of the U.S. population every year, which is equivalent to 3.4 million people. Socioeconomic status and accessibility to care are essential factors affecting the anticonvulsants market in the region. As per the report prepared by the International League Against Epilepsy, the International Bureau for Epilepsy, and the World Health Organization, epileptic patients face an incredibly hard time growing up. They are less likely to be permanently employed and often face stigma throughout their lives. These factors have made the government invest more in the R&D of anticonvulsants, thus increasing market revenue. Furthermore, the anticonvulsants market in the continent of North America has benefitted tremendously by the formation of International League Against Epilepsy- North American chapter constituted in 2006. The league popularizes the idea of anticonvulsants drug as a precise method of seizure reduction in antiepileptic patients. Additionally, North American countries also house several patients suffering from bipolar disorder, which are often prone to seizure activities. According to the USA’s National Institute of Mental Health, 2.8% of the U.S. population was suffering from bipolar disorder in 2017. Bipolar patients often face manic depressive episodes that can be treated by antiepileptic drugs, thus positively impacting the global anticonvulsants market.
Rising Incidence of Epilepsy in Low-Income Countries Positively Impacting the Anticonvulsants Market
Categorized by unpredictable and unusual seizures, epilepsy continues to be a prominent neurological disorder. It affects millions of people every year and makes life extremely difficult for them by causing a lack of confidence and unemployment. According to the WHO, people residing in low-income countries are at a higher risk of dying prematurely owing to epilepsy. Low and middle-income countries lack necessary health facilities that could help people in controlling and monitoring seizures on their own. Further research by the WHO states that 23% of adults with epilepsy are bound to suffer from depression and anxiety. The widespread stigma related to epilepsy has further aggravated the disease as lesser people approach for treatment. Furthermore, due to this associated stigma, epileptic people are experiencing rising unacceptance from the corporate world, thus remaining underemployed or unemployed for most of their lives. Owing to efforts made by the World Health Organization and the Epilepsy Foundation, epilepsy treatment is being integrated into primary services in the healthcare industry in most of the countries. This has majorly helped the anticonvulsants market players in extending the reach of these drugs amongst the epileptic community.
Bipolar Disorder Propelling Growth of the Anticonvulsants Market
Mental illness is one of the leading causes of deaths across the world. According to the World Health Organization, one person dies in every forty seconds owing to suicide. Out of the many mental disorders that affect the human population, bipolar disorder is a prominent one. While suffering from this mental health condition, a person experiences manic and unusual shifts of activity levels and mood. Bipolar disorder and epilepsy can exist in a state of comorbidity, thus creating a scope of growth for the anticonvulsants market. Manic depressive episodes can result in psychic seizures, which has generated a high demand for anticonvulsants. Antiepileptic medication is prescribed to bipolar patients for inducing mood stability by calming hyperactivity experienced by the brain. In some cases, anticonvulsants have been successful in even curing bipolar symptoms permanently. This factor has been indispensable in increasing the usefulness of these drugs in the mental health community, thus increasing the market growth.
Anticonvulsants Market: Key Market Players and Recent Developments
Key market players operating in the anticonvulsants market are Abbott Laboratories, Cephalon, Inc, GlaxoSmithKline PLC., Johnson & Johnson, Novartis AG, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., and UCB Pharma Ltd. In 2018, Novartis AG received approval from the Food and Drug Administration for DISPERZ®, an antiepileptic drug that is used for supplementary treatment of partial-onset seizures in both children and adults who are suffering from tuberous sclerosis. Furthermore, in March 2019, Novartis AG received approval for another anti-seizure drug, albeit partially. Mayzent® is one of a king drug developed by the healthcare organization that helps in reducing symptoms of progressive sclerosis in adults. Pfizer, Inc., on the other hand, is also on the brink of obtaining FDA approval for LYRICA® after conducting successful Phase III trials. This anticonvulsant drug will be used in the treatment of tonic-clonic seizures, which often occur as a result of grand mal epilepsy.
Talk to one of our sales representative about the full report by providing your details in the link below:
Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more our consulting services.
A. Antiepileptic Drugs Market
To request for a proposal, provide your details in the below link:
Mr. Venkat Reddy
Email: [email protected]
Contact Sales: +1-614-588-8538 (Ext-101)
About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.